Birchington, United Kingdom

David Alker

This inventor holds 23 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Other. Active years: 1985-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Alker. Retrieved from https://idiyas.com/inventor/david-alker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0


Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 184(Granted Patents)


Location History:

  • Eastry, Nr. Deal, GB (1985 - 1986)
  • Eastry, GB (1986 - 1987)
  • Margate, GB (1988 - 1990)
  • Birchington, GB (1990 - 1997)
  • Sandwich, GB (1994 - 2002)

Company Filing History:


Years Active: 1985-2002

Loading Chart...
Loading Chart...
Areas of Expertise:
Quaternary Ammonium Compounds
Muscarinic Receptor Antagonists
Dihydropyridine Derivatives
Tachykinin Antagonists
Anticholinergic Agents
1-Arylethyl-3-Substituted Piperidines
Anti-Ischaemic Agents
Antihypertensive Agents
Imidazopyridine PAF/H1 Antagonists
Azetidinylpropylpiperidine Derivatives
2-Oxygen Containing Heteroalkoxyalkyl
23 patents (USPTO):Explore Patents

Title: The Innovative Contributions of David Alker: A Patent Profile

Introduction: David Alker, based in Birchington, GB, is a notable inventor with an impressive portfolio of 23 patents. His innovative work primarily focuses on pharmaceutical compounds and their applications in medicinal chemistry.

Latest Patents: Among his latest patents, David Alker has developed quaternary ammonium compounds, specifically Azetidinylpropylpiperidine derivatives. These compounds are recognized for their potential use as tachykinin antagonists, contributing valuable insights into the field of drug discovery.

Career Highlights: Throughout his career, David has contributed his expertise to leading organizations in the pharmaceutical industry, including Pfizer Corporation. His work has significantly advanced the field of medicinal chemistry and drug development, showcasing his commitment to innovation.

Collaborations: David has collaborated with other esteemed scientists in his field, including Peter E. Cross and Simon F. Campbell. These collaborations have fostered an environment of creativity and innovation, enabling the development of groundbreaking pharmaceutical solutions.

Conclusion: David Alker’s work and accomplishments demonstrate the impact of his contributions to science and innovation. With a strong foundation in drug discovery and a robust patent portfolio, he continues to be a prominent figure in the landscape of pharmaceutical invention.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…